The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England

Journal of Infection

Volumn 65, Issue 1, 2012, Pages 17-24

  van Hoek, Albert Jan ^a   Andrews, Nick ^a   Waight, Pauline A ^a   Stowe, Julia ^a   Gates, Peter ^b   George, Robert ^a   Miller, Elizabeth ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Immunisation Branch   (United Kingdom)

Author keywords

Hospitalisation; Invasive pneumococcal disease; Linkage; Mortality; Risk; Risk groups; Vaccination

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASPLENIA; CEREBROSPINAL FLUID OTORRHEA; CHILD; CHRONIC KIDNEY DISEASE; CHRONIC LIVER DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; COCHLEA PROSTHESIS; COHORT ANALYSIS; DIABETES MELLITUS; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HEART DISEASE; HERD IMMUNITY; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFECTION RISK; MAJOR CLINICAL STUDY; MEDICAL RECORD; MORTALITY; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SEROTYPE; SPLEEN DISEASE; UNITED KINGDOM; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; CHILD; CHILD, PRESCHOOL; COMORBIDITY; ENGLAND; FEMALE; HUMANS; IMMUNITY, HERD; MALE; MENINGITIS, PNEUMOCOCCAL; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PREVALENCE; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84861481752     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.02.017     Document Type: Article

References (28)

1. The H1N1 swine flu vaccination programme 2009-2010 Chief Medical Officer Letter 15 October 2009, Department of Health, [accessed August 25, 2011]. http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_107169.
2. Baguelin M., Hoek A.J., Jit M., Flasche S., White P.J., Edmunds W.J. Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. Vaccine 2010 Mar 11, 28(12):2370-2384. Epub 2010 Jan.
3. Pebody R.G., Hippisley-Cox J., Harcourt T., Pringle M., Painter M., Smith G. Uptake of pneumococcal polysaccharide vaccine in at-risk populations in England and Wales 1999-2005. Epidemiol Infect 2008, 136:360-369.
4. Immunisation against infectious disease - The Green Book. Available from: [accessed August 25, 2011]. http://www.dh.gov.uk/en/Publichealth/Immunisation/Greenbook/index.htm.
5. Shapiro E.D., Berg A.T., Austrian R., Schroeder D., Parcells V., Margolis A., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. Engl J Med 1991 Nov 21, 325(21):1453-1460.
6. Butler J.C., Breiman R.F., Campbell J.F., Lipman H.B., Broome C.V., Facklam R.R. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993 Oct 20, 270(15):1826-1831.
7. French N., Gordon S.B., Mwalukomo T., White S.A., Mwafulirwa G., Longwe H., et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010 Mar 4, 362(9):812-822.
8. Musher D.M., Sampath R., Rodriguez-Barradas M.C. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence?. Clin Infect Dis 2011 Mar, 52(5):633-640.
9. JCVI Agenda and meeting papers. Report from the JCVI pneumococcal sub-committee; 2 February 2011. Available from: [accessed August 25, 2011]. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/%40dh/%40ab/documents/digitalasset/dh_125139.pdf.
10. JCVI Agenda and meeting papers. Possible costs of wider use of PCV13; 2 February 2011. Available from: [accessed August 25, 2011]. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/%40dh/%40ab/documents/digitalasset/dh_125137.pdf.
11. Key vaccine information: pneumococcal. Department of Health. Available from: [accessed August 25, 2011]. http://www.dh.gov.uk/en/Publichealth/Immunisation/Keyvaccineinformation/DH_103944.
12. PRIMIS+ READ code specification. Available from: [accessed August 25, 2011]. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_103940.pdf.
13. PRIMIS+ logical query definition. Available from: [accessed August 25, 2011]. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_103941.pdf.
14. READ codes. Available from: [accessed August 25, 2011]. http://www.connectingforhealth.nhs.uk/systemsandservices/data/uktc/readcodes.
15. Office for National Statistics. Mid year population estimates, England and Wales. Available from: [accessed August 25, 2011]. http://www.statistics.gov.uk/statbase/Product.asp%3Fvlnk%3D15106.
16. Trotter C.L., Waight P., Andrews N.J., Slack M., Efstratiou A., George R., et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996-2006. J Infect 2009 Dec, 60:200-208. Available from:, [Internet]. http://dx.doi.org/10.1016/j.jinf.2009.12.008.
17. Miller E., Andrews N.J., Waight P.A., Slack M.P.E., George R.C. Herd immunity and serotype replacement four years after pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011 Oct, 11(10):760-768.
18. Hospital Episode Statistics, The Health and Social Care Information Centre. Available from: [accessed August 25, 2011]. http://www.hesonline.org.uk.
19. Harboe Z.B., Thomsen R.W., Riis A., Valentiner-Branth P., Christensen J.J., Lambertsen L., et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009 May 26, 6(5).
20. Klemets P., Lyytikäinen O., Ruutu P., Ollgren J., Pekka Nuorti J. Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. BMC Infect Dis 2008 Jul 22, 8:96.
21. Hjuler T., Wohlfahrt J., Staum Kaltoft M., Koch A., Biggar R.J., et al. Risks of invasive pneumococcal disease in children with underlying chronic diseases. Pediatrics 2008 Jul, 122(1).
22. Pilishvili T., Zell E.R., Farley M.M., Schaffner W., Lynfield R., NYquist A.C., et al. Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use. Pediatrics 2010, 126:e9-e17.
23. Flasche S., van Hoek A.J., Sheasby E., Waight P., Andrews N., et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in england: a cross-sectional study. PLoS Med 2011, 8(4):e1001017. 10.1371/journal.pmed.1001017.
24. Sjöström K., Spindler C., Ortqvist A., Kalin M., Sandgren A., Kühlmann-Berenzon S., et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 2006 Feb 15, 42(4):451-459.
25. Talbot T.R., Hartert T.V., Mitchel E., Halasa N.B., Arbogast P.G., Poehling K.A., et al. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med 2005 May 19, 352(20):2082-2090.
26. Klemets P., Lyytikäinen O., Ruutu P., Ollgren J., Kaijalainen T., Leinonen M., et al. Risk of invasive pneumococcal infections among working age adults with asthma. Thorax 2010 Aug, 65(8):698-702.
27. Yin Z., Rice B., Waight P.A., Miller E., George R., Brown A., et al. Invasive pneumococcal disease among HIV positive individuals in England and Wales, 2000-2009. AIDS 2012 Jan, 26(1):87-94.
28. Hsu K.K., Shea K.M., Stevenson A.E., Pelton S.I. Underlying conditions in children with invasive pneumococcal disease in the conjugate vaccine era. Pediatr Infect Dis J 2011 Mar, 30(3):251-253. Members of the Massachusetts Department of Public Health.